DPP-4 Inhibition targeting the Gut–Brain Axis in Parkinson's Disease: Gut | July 2026
Introduction:
Increasing evidence suggests that Parkinson's disease (PD) may originate in the gut, with pathological α-synuclein spreading to the brain through the vagus nerve. This preclinical study investigated whether sitagliptin, a widely used DPP-4 inhibitor, could modify gut–brain axis pathology and slow PD progression.
Why was this study needed?
- The gut–brain axis is increasingly recognized as a key driver of Parkinson's disease.
- Neuroinflammation and α-synuclein propagation remain attractive therapeutic targets.
- DPP-4 inhibitors have shown potential neuroprotective effects, but their mechanism in PD is unclear.
- Drug repurposing could accelerate the availability of disease-modifying therapies.
- The relationship between DPP-4 inhibition, gut microbiota, and PD progression required investigation.
Results:
- Sitagliptin reduced gut inflammation, suppressed TLR2-mediated immune activation, and decreased α-synuclein accumulation in the intestine, vagus nerve, and brain, resulting in improved motor function.
- The drug protected neurons in the brainstem and midbrain and demonstrated anti-inflammatory effects across multiple gut cell types, including macrophages, enteric glial cells, and enteroendocrine cells.
- Sitagliptin favorably remodeled the gut microbiome, and its neuroprotective effects persisted even after GLP-1 receptor blockade, suggesting mechanisms beyond incretin signaling.
Clinical Impact:
This study identifies DPP-4 inhibition as a promising drug-repurposing strategy for Parkinson's disease by targeting the gut–brain axis rather than the brain alone. The findings highlight TLR2-mediated inflammation, α-synuclein propagation, and gut microbiome modulation as potential therapeutic targets that warrant evaluation in clinical trials.
Bottom Line:
Sitagliptin reduced gut inflammation, limited α-synuclein spread from the gut to the brain, improved motor function, and reshaped the gut microbiome in a preclinical Parkinson's disease model. These findings support further investigation of DPP-4 inhibitors as potential disease-modifying therapies for Parkinson's disease.
